Cardiac monitoring in HER2-positive patients on trastuzumab treatment …
Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is …
How to Manage and Monitor Cardiac Dysfunction in Patients …
Sep 20, 2022 · The frequency of cardiac monitoring should be based on a risk-benefit approach. The introduction of human epidermal growth factor receptor 2 (HER2)–targeted therapies into …
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy …
Feb 1, 2016 · The SAFE-HEART (A Pilot Study Assessing the Cardiac Safety of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular …
What to Expect During Treatment with Herceptin® (trastuzumab) for HER2 ...
What to expect with Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer including monitoring potential side effects, heart monitoring and testing during treatment. See …
Cardiac surveillance for anti-HER2 chemotherapy
Feb 1, 2021 · Anti-human epidermal growth factor receptor 2 (anti-HER2) therapy has been a game-changer for some forms of aggressive breast cancer, drastically reducing mortality …
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk | HER2-Positive …
Learn about Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk), a subcutaneous injection for eligible patients with HER2-positive breast cancer. See Full Safety and BOXED …
Herceptin for HER2-Positive Breast Cancer - HealthCentral
Nov 7, 2024 · Herceptin, a HER2 inhibitor targeted therapy, treats breast cancer. Learn if it's right for you and more here.
Side Effects to Monitor During HER2-Positive Breast Cancer Treatment
Jun 26, 2024 · For each line of treatment received for HER2-positive metastatic breast cancer, it's important to know what side effects to monitor. There are side effects that patients need to be …
Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (SENTRY-HER2)
Sep 25, 2025 · Participants must have histologically or cytologically confirmed HER2 positive solid tumor cancers that has progressed during or following previous anti-cancer treatment.
Heart failure prevention and monitoring strategies in HER2-positive ...
Cardiotoxicity from anti-human epidermal growth factor receptor 2 (HER2) therapy carries a short- and long-term risk of incident heart failure and increased cardiovascular mortality in patients …